Advocare Long Logo

The Allergy & Clinical Immunology Center

NEW Peanut Vaccine Trial Part B
If you or someone you know is 18-23 years old and has a physician diagnosed peanut allergy, this exciting new clinical trial may interest you! Click for details.
 
If you or someone you know is 18-23 years old and has a physician diagnosed peanut allergy, this exciting new clinical trial may interest you!
 
The PROTECT study is a Phase I trial that is looking to test the safety and efficacy of a peanut vaccine called VLP peanut. Scientists have found that when proteins that cause the allergic reaction to peanut are included in the virus-like particle (VLP), they may bypass the immune cells responsible for the allergic reaction and can help train your immune system to tolerate peanut. This vaccine could potentially protect against an allergic reaction to peanut in the future.
 
If you would like to learn more about the study, please contact the study’s research coordinator at madeleine.peel@mssm.edu.
NEW Peanut Vaccine Trial Part B
Share by: